Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melita Kenealy

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The New England Journal of Medicine|June 15, 2026
Immunosuppression-Associated Peripheral T-Cell LymphomaEdward Robert Scheffer Cliff, Melita Kenealy
Expert Review of Anticancer Therapy|October 20, 2007
Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agentsMark Bishton, Melita Kenealy, Ricky Johnstone, et al.
Leukemia & Lymphoma|September 20, 2012
Treatment of chronic myelomonocytic leukemia with azacitidineEric Wong, John F Seymour, Melita Kenealy, et al.
Leukemia & Lymphoma|December 17, 2021
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemiaZoe K McQuilten, Ljoudmila Busija, John F Seymour, et al.
Haematologica|November 4, 2006
Treatment-related myelodysplasia following fludarabine combination chemotherapyConstantine S Tam, John F Seymour, H Miles Prince, et al.
Ejhaem|November 29, 2023
Favorable outcomes of <i>DDX41</i>-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomideIng S Tiong, William S Stevenson, Meaghan Wall, et al.
European Journal of Haematology|December 28, 2021
Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)Lynette Chee, David Ritchie, Mandy Ludford-Menting, et al.
Leukemia & Lymphoma|October 27, 2006
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancySteven W Lane, Julie Crawford, Melita Kenealy, et al.
Leukemia & Lymphoma|June 9, 2016
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)Melita Kenealy, Nigel Patton, Robin Filshie, et al.
Leukemia & Lymphoma|October 30, 2009
IgA nephropathy associated with cutaneous T cell lymphomaAshish Bajel, Ming Yin Lin, Prudence A Hill, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The New England Journal of Medicine|June 15, 2026
Immunosuppression-Associated Peripheral T-Cell LymphomaEdward Robert Scheffer Cliff, Melita Kenealy
Expert Review of Anticancer Therapy|October 20, 2007
Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agentsMark Bishton, Melita Kenealy, Ricky Johnstone, et al.
Leukemia & Lymphoma|September 20, 2012
Treatment of chronic myelomonocytic leukemia with azacitidineEric Wong, John F Seymour, Melita Kenealy, et al.
Leukemia & Lymphoma|December 17, 2021
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemiaZoe K McQuilten, Ljoudmila Busija, John F Seymour, et al.
Haematologica|November 4, 2006
Treatment-related myelodysplasia following fludarabine combination chemotherapyConstantine S Tam, John F Seymour, H Miles Prince, et al.
Ejhaem|November 29, 2023
Favorable outcomes of <i>DDX41</i>-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomideIng S Tiong, William S Stevenson, Meaghan Wall, et al.
European Journal of Haematology|December 28, 2021
Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS)Lynette Chee, David Ritchie, Mandy Ludford-Menting, et al.
Leukemia & Lymphoma|October 27, 2006
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancySteven W Lane, Julie Crawford, Melita Kenealy, et al.
Leukemia & Lymphoma|June 9, 2016
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)Melita Kenealy, Nigel Patton, Robin Filshie, et al.
Leukemia & Lymphoma|October 30, 2009
IgA nephropathy associated with cutaneous T cell lymphomaAshish Bajel, Ming Yin Lin, Prudence A Hill, et al.
Pageof 2